DelveInsight’s, “Treatment-Resistant Hypertension Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Treatment Resistant Hypertension pipeline landscape. It covers the Treatment Resistant Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Treatment Resistant Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight’s comprehensive Treatment-Resistant Hypertension Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight
Key Takeaways from the Treatment-Resistant Hypertension Pipeline Report
- On January 12, 2026- United Therapeutics conducted a Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
- DelveInsight’s Treatment Resistant Hypertension pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Treatment Resistant Hypertension treatment.
- The leading Treatment Resistant Hypertension Companies such as Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences and others.
- Promising Treatment Resistant Hypertension Therapies such as CIN-107, Aprocitentan 12.5 mg, Patiromer, Spironolactone, Firibastat, LHW090, Darusentan and others.
Access DelveInsight’s in-depth Treatment-Resistant Hypertension Pipeline Analysis for a closer look at promising breakthroughs @ Treatment-Resistant Hypertension Clinical Trials and Studies
Treatment-Resistant Hypertension Emerging Drugs Profile
- Psilocybin: COMPASS Pathways
Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. The company has developed a synthesised formulation of psilocybin, COMP 360, and is investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression.
- AXS-05: Axsome Therapeutics
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. These actions modulate glutamatergic neurotransmission. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor
The Treatment-Resistant Hypertension Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Treatment Resistant Hypertension with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Treatment Resistant Hypertension Treatment.
- Treatment Resistant Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Treatment Resistant Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Treatment Resistant Hypertension market.
Explore DelveInsight’s expert-driven report today! @ Treatment-Resistant Hypertension Unmet Needs
Treatment-Resistant Hypertension Companies
Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences and others.
Treatment-Resistant Hypertension Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Treatment-Resistant Hypertension Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Download DelveInsight’s latest report to gain strategic insights into upcoming Therapies and key Developments @ Treatment-Resistant Hypertension Market Drivers and Barriers, and Future Perspectives
Scope of the Treatment-Resistant Hypertension Pipeline Report
- Coverage- Global
Treatment Resistant Hypertension Companies- Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences and others.
- Treatment Resistant Hypertension Therapies- CIN-107, Aprocitentan 12.5 mg, Patiromer, Spironolactone, Firibastat, LHW090, Darusentan and others.
- Treatment Resistant Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Treatment Resistant Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find out in DelveInsight’s exclusive Treatment-Resistant Hypertension Pipeline Report—access it now! @ Treatment-Resistant Hypertension Emerging Drugs and Major Companies
Table of Content
- Introduction
- Executive Summary
- Treatment Resistant Depression: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Preregistration)
- AXS-05: Axsome Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Psilocybin: COMPASS Pathways
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- SEP-378614: Sumitomo Dainippon Pharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Inactive Products
- Treatment Resistant Depression Key Companies
- Treatment Resistant Depression Key Products
- Treatment Resistant Depression- Unmet Needs
- Treatment Resistant Depression- Market Drivers and Barriers
- Treatment Resistant Depression- Future Perspectives and Conclusion
- Treatment Resistant Depression Analyst Views
- Treatment Resistant Depression Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight